Clinical trial BGB-3111-306
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Cancers | |
---|---|
Organ | Non-Hodgkin lymphoma |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | BeiGene |
EudraCT Identifier | 2019-000413-36 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04002297 |
Inclusion criteria | MCL; 70 years or 65 years with co-morbidities that contraindicate autograft; ECOG 2 |
Last update |